הכנסה תפעולית לפני ניכוי פחת: Surrozen (SRZN)

The EBITDA_Co chart demonstrates the current resilience of Surrozen, Inc. (SRZN), where the parameter value equals 0.00. Surrozen, Inc. (SRZN) is developing the Wnt regenerative platform to combat intestinal and liver pathologies, leveraging support from Boehringer. Revenues are based on grants for researching new therapy methods. Currently, payments from major pharma partners for access to selective modeling form the financial foundation.

Identifying fundamentally resilient assets requires an analysis of cash flow from operations before depreciation and interest. This metric measures the actual ability to generate cash, which is critical for Surrozen, Inc. (SRZN) due to costly stem cell research and a lack of profitability; therefore, the size of cash EBITDA serves as an indicator of the company's viability amidst high investment risks.